ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The treatment of CML is based on a series of small molecules inhibiting the TK of BCR-ABL, including dasatinib, imatinib, nilotinib, bosutinib, and ponatinib (Jabbour, 2016).